The invention provides new methods of treatment using TGF-&bgr；3 to inhibit scarring in humans, and TGF-&bgr；3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment TGF-&bgr；3 is provided to each centimetre of a wound margin or each centimetre of a site at which a wound is to be formed in a first therapeutically effective amount； and in a subsequent incidence of treatment TGF-&bgr；3 is provided to each centimetre of wound margin in a larger therapeutically effective amount of TGF-&bgr；3. The incidences of treatment occur between 8 hours and 48 hours apart from one another. The TGF-&bgr；3 may be provided by intradermal injection. Also provided are kits and methods of selecting an appropriate treatment regime for inhibiting scarring associated with the healing of a human wound.
